U.S. pharmaceutical research services provider Parexel International Corp said on Tuesday it would be taken private by Pamplona Capital Management LLP in a $4.5 billion deal.
Activist investors, including Starboard Value LP, have put pressure on Parexel to explore a sale, arguing that the company’s profit margins have consistently lagged those of its peers.
Pamplona will pay $88.10 per share in cash for Parexel, representing a 5 percent premium to the stock’s Monday close. Parexel’s shares were trading at $87.67 before the bell, just shy of the offer price.
The stock has jumped more than 20 percent since the first report of a potential sale appeared in May.
Including debt, the deal is valued at $5 billion.
Headquartered near Boston, Massachusetts, Parexel provides a range of services to the pharmaceutical industry, ranging from drug development and regulatory consulting to clinical pharmacology, clinical trials management and reimbursement.
The company focuses on cancer drug research and has a platform for so-called “real-world” data, which can be used to assess the economic value of medicines and is sought after by drug makers looking to justify their prices to health insurers.
Pamplona had been scouring the market in the last year, seeking to acquire a contract research organization. It made an unsuccessful bid earlier this year for Pharmaceutical Product Development LLC (PPD), a U.S. clinical trials firm valued at more than $9 billion.
The contract research industry has been undergoing a wave of consolidation as pharmaceutical companies cut costs, reduce clinical trial times and expand their research and development presence around the world.
Deal-making also allows companies to profit from economies of scale, as they seek to boost their real-world data gathering capabilities.
Last month, INC Research Holdings Inc agreed to merge with inVentiv Health Inc in a $4.6 billion deal. Contract researcher Quintiles Transnational Holdings Inc completed a $9 billion merger with IMS Health Holdings Inc last year.
The Parexel deal is expected to close in the fourth quarter.
Goldman Sachs is Parexel’s financial adviser, while Goodwin Procter LLP served as legal adviser. Perella Weinberg Partners LP Pamplona’s financial adviser, while Kirkland & Ellis LLP is their legal adviser.
By Carl O’Donnell in New York
Novo Holdings has concluded the acquisition of all outstanding shares of commercial-stage biopharmaceutical company Paratek Pharmaceuticals for nearly $462m (€433.67m) to bolster its antimicrobial resistance (AMR) expertise. Paratek develops and commercialises new treatments for life-threatening ailments. Its speciality pharmaceutical platform aids in developing new therapeutics.
Glenmark Pharmaceuticals has signed a definitive agreement for the divestiture of a 75% stake in its division, Glenmark Life Sciences (GLS), to Indian company Nirma in a deal valued at Rs56.51bn ($679.85m). Glenmark Life Sciences focuses on producing active pharmaceutical ingredients (API).
Pierre-Alain Ruffieux, CEO of Lonza, will leave the Basel-based company at the end of September. According to the Swiss Contract Development and Manufacturing Organization (CDMO), the separation is by mutual agreement.